Oculis (NASDAQ:OCS) Stock Price Up 9% – Time to Buy?

Shares of Oculis Holding AG (NASDAQ:OCS) shot up 9% on Tuesday . The company traded as high as $11.63 and last traded at $11.6790. 240,161 shares were traded during mid-day trading, a decline of 52% from the average session volume of 496,844 shares. The stock had previously closed at $10.71.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Robert W. Baird lowered their target price on shares of Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a research note on Monday, June 1st. Stifel Nicolaus reduced their price objective on shares of Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, June 1st. JPMorgan Chase & Co. decreased their price objective on shares of Oculis from $42.00 to $23.00 and set an “overweight” rating for the company in a research note on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. Finally, Guggenheim reduced their price target on shares of Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.33.

Oculis Trading Down 0.1%

The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $25.62 and a 200-day moving average price of $24.80. The firm has a market capitalization of $636.04 million, a PE ratio of -5.15 and a beta of 0.23.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The company had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. Analysts expect that Oculis Holding AG will post -2.27 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of OCS. Gildi lifeyrissjodur purchased a new stake in shares of Oculis in the fourth quarter valued at $50,250,000. Aberdeen Group plc boosted its stake in shares of Oculis by 39.4% during the 4th quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after purchasing an additional 493,827 shares during the last quarter. SR One Capital Management LP grew its holdings in shares of Oculis by 98.8% during the fourth quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock worth $12,801,000 after buying an additional 318,522 shares in the last quarter. Perceptive Advisors LLC acquired a new position in shares of Oculis in the fourth quarter valued at approximately $9,862,000. Finally, Alyeska Investment Group L.P. lifted its stake in shares of Oculis by 152.3% during the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after buying an additional 200,000 shares during the period. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.